Magnetic tracking and ECG-guided tip confirmation for PICC placement
Official title: Magnetic Tracking and Electrocardiography-Guided Tip Confirmation System for Placement of Peripherally Inserted Central Catheters
Run by Sun Yat-sen University · NCT07369427 · Data updated 2026-11-12
This project tests whether a magnetic tracking tip confirmation system (Sherlock 3CG) leads to more accurate and faster PICC tip placement than traditional ECG-guided positioning in cancer patients at high risk for PICC-related thrombosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 176 (estimated) |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | May 30, 2026 |
| Study ends | June 30, 2026 |
| Registry record updated | May 7, 2026 |
| Trial ID | NCT07369427 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are cancer patients receiving PICC placement who are at high risk for PICC-related thrombosis (Caprini score ≥ 5), agree to PICC maintenance at the research hospital, and can provide informed consent.
✕Probably not a fit
Patients with PICCs placed in the lower limb or those with estimated survival under one month are excluded and unlikely to benefit from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational study enrolled cancer patients receiving PICC placement at a tertiary oncology center in Guangzhou between January 1 and May 30, 2026. Patients underwent tip positioning either with electromagnetic navigation using the Sherlock 3CG system or with standard ECG-guided confirmation, and procedural details were recorded. Outcomes included first-attempt success rate, tip positioning accuracy, procedure time, post-procedural catheter adjustment time, and complications (thrombosis, infection, catheter dysfunction) within 4 weeks. The two techniques were compared to determine whether magnetic tracking offers advantages in accuracy, speed, or complication reduction for a high-risk oncology population.
Why it matters
Potential benefit: If successful, the magnetic tracking approach could reduce malposition and the need for post-procedure adjustments, improving safety and convenience for high-risk cancer patients with PICCs.
How similar studies have gone: Previous work with electromagnetic tip confirmation systems like Sherlock 3CG has shown improved tip placement accuracy and reduced need for post-procedure X-rays in many settings, although results can vary by center and patient group.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * cancer patients receiving PICC placement * High risk of PICC-related thrombosis(Evaluated by Caprini score ≥ 5) * Agree to receive PICC maintenance at the research hospital; * Sign the informed consent form Exclusion Criteria: * PICC placed in the lower limb * Estimated survival time less than one month
Where it's running
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Zeyin Hu, Master
- Email: huzy@sysucc.org.cn
- Phone: +8615899954190
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Anatomic vs nonanatomic liver resection after conversion therapy for liver cancer
This study tests whether removing more precisely targeted liver tissue (anatomic resection) works better than removing tissue more broadly (nonanatomic) for patients whose unresectable liver cancer became eligible for surgery after PD-1/PD-L1–based therapy.
-
AI-assisted imaging for diagnosing and managing focal liver lesions
Researchers are testing whether AI-powered imaging can help doctors better diagnose focal liver lesions in adults undergoing CT scans.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
-
Anlotinib Plus PD-1 Inhibitor vs PD-1 Inhibitor Alone After Chemoimmunotherapy in Advanced ESCC
This trial tests whether adding anlotinib to PD-1 inhibitor maintenance after initial chemoimmunotherapy helps people with advanced esophageal squamous cell carcinoma live longer without the cancer growing.
-
Cryoablation with liver-directed immunotherapy and targeted therapy for melanoma liver metastases
This trial tests a combination therapy including cryoablation, hepatic artery delivery of QL1706, intravenous dacarbazine, and oral lenvatinib to treat liver metastases from malignant melanoma in adults.
-
HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma
This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.